The Chi-square test of the PARP10 expression group (i.e., high vs. low) and clinical characteristics demonstrated that the high expression of PARP10 was associated with older age, more frequent TP53 mutations, and higher risk classifications, all of which exhibited features of high AML risk and were consistent with the result of predicting inferior clinical outcomes. The gene discussed is PARP10; the disease is acute myeloid leukemia.